4D pharma plc, headquartered in Leeds, UK, and founded in 2014 (originally Schosween 18 Limited), functions as a biopharmaceutical firm dedicated to pioneering live biotherapeutic products (LBPs). The company's diverse pipeline includes several therapeutic candidates aimed at various significant health issues: MRx0518 is being developed to address cancer and immune-oncology diseases. MRx-4DP0004 targets asthma. MRx0029 and MRx0005 are in development for central nervous system disorders. Blautix is intended for irritable bowel syndrome. Thetanix focuses on pediatric Crohn's disease. Additional candidates encompass MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. To drive its discovery efforts, 4D pharma plc utilizes its proprietary MicroRx platform, designed to unearth new LBP candidates for severe illnesses. The company has also established key collaborations: A partnership with Merck KGaA (Darmstadt, Germany) and Pfizer for the assessment of MRx0518. A strategic alliance with the University of Texas MD Anderson for the discovery and development of LBPs within oncology. An agreement with Merck & Co., Inc. involves a clinical trial evaluating the combination of Keytruda and MRx0518 in solid tumor patients, alongside joint initiatives to discover and develop LBPs for vaccine purposes.